TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/26/24 12:50 | 4/25/24 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | MI | O | CEO | M.d | 25 | 11.96 | 0 | 2 | 1 | 171 | D | ||||||||||||||
4/10/24 14:25 | 4/10/24 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | MI | O | CEO | P | 284 | 12.36 | 0 | 23 | 18 | 152 | D | ||||||||||||||
9/28/22 17:27 | 9/28/22 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | CO | DO | P,CEO | P | 316 | 14.37 | 0 | 22 | 38 | 80 | D | ||||||||||||||
8/2/22 14:28 | 7/29/22 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Adent John Edward | CO | DO | P,CEO | P | 404 | 23.07 | 0 | 18 | 43 | 58 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |